The Latest Cardiac and Vascular News
– Generated 38.8% growth in CGuard™ revenue year-over-year – – Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete enrollment by approximately end of Q1 2023 – – Announced strategic partnership with […]
– Generated 47.8% growth in CGuard™ revenue year-over-year – – Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission – – Announced that endovascular pioneer Dr. Juan Parodi has agreed to act as strategic advisor […]
Credited with performing the first ever endovascular repair procedure in 1990 TEL AVIV, Israel, July 14, 2022 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced the […]
– 20% growth in CGuard™ revenue Year-over-Year – – C-Guardian FDA IDE Trial Completes First European Enrollment – – Held Key Opinion Leader (KOL) Webinar on Carotid Artery Disease Management and Stroke Prevention, highlighting CGuard™ clinical advantages – – European logistics […]
– CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year –- – Published CGuard Clinical trial results in Journals of the American College of Cardiology – – Established Reimbursement Approval for CGuard from the French National Authority – – […]
– CGuard™ Carotid Stent will now be a treatment option in the stenting plus medical therapy arm of the trial for patients – – CREST-2 Trial is sponsored by the National Institute of Neurological Disorders and Stroke (NINDS) and actively engaged at […]
Dr. Siddiqui is recognized for his extensive experience in Microsurgical, Radiosurgical and Endovascular Techniques for the Comprehensive Management of Vascular Disease TEL AVIV, Israel, Feb. 15, 2022 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ […]
Live Case will be Broadcasted Today at 11:00am ET TEL AVIV, Israel, Jan. 18, 2022 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease […]
-CGuard™ sales generated 24% YoY revenue growth- -CGuard™ EPS received a positive opinion from the French National Authority for Health (HAS) regarding reimbursement in France- – $37.1 million in cash, cash equivalents and short-term bank deposits as of September 30, […]
TEL AVIV, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from […]
